Disability progression after switching from natalizumab to fingolimod or interferon beta/glatiramer acetate therapies: A NARCOMS analysis
- Stacey S. Cofield
- , Robert J. Fox
- , Tuula Tyry
- , Amber R. Salter
- , Denise Campagnolo
Research output: Contribution to journal › Article › peer-review
5
Link opens in a new tab
Scopus
citations